Sakar Healthcare Reports Strong Q2FY27 Results With 149% YoY PAT Surge
Sakar Healthcare Ltd · Press Release · 26 Oct 2026, 7:30 pm
Sakar Healthcare Reports Strong Q2FY27 Results With 149% YoY PAT Surge Sakar Healthcare reported robust Q2FY27 consolidated performance, with revenue from operations growing 52% YoY to ₹8,741.61 lakhs. EBITDA jumped 114% YoY to ₹2,434.53 lakhs with margins expanding 800 bps to 28%, while PAT surged 149% YoY to ₹1,130.69 lakhs (13% margin), driven by favorable oncology mix and operational leverage. For H1FY27, revenue reached ₹16,038.86 lakhs and PAT stood at ₹2,159.18 lakhs. Growth was supported by commencement of commercial supplies from its EU-GMP approved oncology site, 69 executed contracts, and regulatory advancements.
Original exchange filing (PDF)
More announcements from Sakar Healthcare Ltd
- Sakar Healthcare Limited has informed the Exchange about Transcript · 02 Nov 2026
- Sakar Healthcare Limited has informed the Exchange about Link of Recording · 27 Oct 2026
- Sakar Healthcare Limited has informed the Exchange about Investor Presentation · 26 Oct 2026
- Sakar Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 23 Oct 2026
- Sakar Healthcare Limited has informed the Exchange about Schedule of meet · 27 Oct 2026
- SAKAR HEALTHCARE LIMITED has informed the Exchange about Board Meeting to be held on 23-Oct-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business. · 23 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 and other business matters · 23 Oct 2026
- Sakar Healthcare Limited has informed the Exchange about Sakar s global export model expands with oncology products · 14 Oct 2026
